文献速递肝病

荟萃分析:增强型肝纤维化检测用于识别慢性肝病患者的肝纤维化

Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-17

该荟萃分析纳入63项研究、19,285例慢性肝病患者,评估增强型肝纤维化(ELF)检测对照组织学诊断肝纤维化的准确性。显著纤维化、进展期纤维化和肝硬化的患病率分别为47.5%、39.2%和4.4%。最大约登指数切点的AUROC分别为0.811、0.812和0.810。作者认为ELF在各病因间的分期能力差异较大,酒精相关肝病和基层患者的数据不足。

要点

  • ELF检测区分显著纤维化、进展期纤维化和肝硬化的AUROC分别为0.811、0.812和0.810。
  • 纳入63项研究共19,285例患者,显著纤维化、进展期纤维化和肝硬化患病率分别为47.5%、39.2%和4.4%。
  • 作者指出ELF在各病因间分期能力差异较大,酒精相关肝病和基层数据不足。

核心结论

  • 荟萃分析显示,ELF检测在各病因的肝纤维化分期能力上存在相当大的变异性。
  • 研究多集中于病毒性肝炎和非酒精性脂肪性肝病(NAFLD)。
  • 目前缺乏ELF检测在酒精相关肝病和基层患者中价值的数据。

研究设计与样本

  • 检索PubMed和EMBASE(2020年10月至2021年11月),纳入报告ELF检测对比组织学诊断准确性的研究。
  • 采用QUADAS-2评估每项研究的偏倚风险。
  • 使用Steinhauser等描述的多阈值模型荟萃分析,合并不同切点的2×2数据。
  • 共纳入63项研究、19,285例确诊或存在肝病风险的患者,涵盖病毒性肝炎、NAFLD、酒精相关肝病及其他混合慢性肝病。

主要发现

  • 显著纤维化、进展期纤维化和肝硬化的患病率分别为47.5%、39.2%和4.4%。
  • 最大约登指数切点检测显著纤维化的AUROC为0.811(95%CI:0.736-0.870)。
  • 最大约登指数切点检测进展期纤维化的AUROC为0.812(95%CI:0.758-0.856)。
  • 最大约登指数切点检测肝硬化的AUROC为0.810(95%CI:0.694-0.888)。
  • ELF检测的诊断准确性在不同肝病和切点之间存在差异,并生成了各分期达到95%灵敏度或特异度的切点。

局限性

  • 作者指出ELF在各病因间的纤维化分期能力存在相当大的变异性。
  • 研究多集中于病毒性肝炎和NAFLD。
  • 目前缺乏ELF检测在酒精相关肝病和基层患者中价值的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with liver disease can be stratified for risk of liver-related ill health by degree of hepatic fibrosis. The Enhanced liver fibrosis (ELF) test was developed to quantify hepatic fibrosis non-invasively and is widely used. The objective of this review was to identify and synthesise the evidence on the diagnostic accuracy of the ELF test for staging of hepatic fibrosis. APPROACH & RESULTS: Searches of PubMed and EMBASE were conducted between October 2020 and November 2021 to identify studies reporting the diagnostic accuracy of the ELF test compared to histology in liver disease patients. QUADAS-2 was used to assess risk of bias in each study. Meta-analysis using the multiple thresholds model described by Steinhauser S, Schumacher M, Rücker G. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies. BMC Med. Res. Methodol. 2016;16. 10.1186/s12874-016-0196-1 allowed synthesis of 2 × 2 data at different cut-offs. Sixty-three studies were included in this review. These studies included 19,285 patients with or at risk of liver disease from viral hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-related Liver Disease and other mixed chronic liver diseases. The prevalence of significant fibrosis, advanced fibrosis and cirrhosis was 47.5%, 39.2% and 4.4%, respectively. Cut-offs with maximal Youden index were generated with AUROC = 0.811 (95% CI: 0.736-0.870), 0.812 (95% CI: 0.758-0.856) and 0.810 (95% CI: 0.694-0.888) to detect significant fibrosis, advanced fibrosis or cirrhosis, respectively. Diagnostic accuracy of the ELF test varied between different liver diseases and cut-offs to detect each stage with 95% sensitivity or specificity were also generated. CONCLUSIONS: Meta-analysis revealed considerable variability in the ability of ELF to stage fibrosis across disease aetiologies. Research has mostly focused on viral hepatitis and NAFLD. There is currently a lack of data on the value of the ELF test in Alcohol-related liver disease and patients in primary care settings.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hinkson A, Lally H, Gibson H, et al. Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther. 2023. PMID: 36650720. doi:10.1111/apt.17385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。